Local Anesthetic in Total Knee Arthroplasty (TKA): Volume Versus Concentration
Phase 4
Completed
- Conditions
- Postoperative PainAnalgesic Efficacy
- Interventions
- Drug: 20 mL ropivacaine 5 mg/mLDrug: 10 mL ropivacaine 10 mg/mL
- Registration Number
- NCT01012232
- Lead Sponsor
- Lundbeck Foundation
- Brief Summary
In a randomized, double-blind, cross-over trial, 48 patients scheduled for total knee arthroplasty with placement of an intracapsular catheter will be randomized to receive bolus injection of ropivacaine in high volume/low concentration (20 ml, 5 mg/mL) or low volume/high concentration (10 mL, 10 mg/mL) 6 and 24 hours postoperatively, and pain will be assessed at rest and with mobilization for 2 hours after injections.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 48
Inclusion Criteria
- Scheduled for total knee arthroplasty
- Able to give informed oral and written consent to participate
Exclusion Criteria
- Treatment with opioids or steroids, rheumatoid arthritis or other immunological diseases
- History of stroke or any neurological or psychiatric disease potentially influencing pain perception (e.g. depression, diabetic neuropathy etc.)
- Allergies to any of the drugs administered.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description high volume local anesthetic 20 mL ropivacaine 5 mg/mL bolus injection of ropivacaine in high volume/low concentration (20 ml, 5 mg/mL) low volume local anesthetic 10 mL ropivacaine 10 mg/mL bolus injection of local anesthetic in low volume/high concentration (10 mL, 10 mg/mL)
- Primary Outcome Measures
Name Time Method postoperative pain 32 hours postoperative
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Lundbeck Centre for fast-track hip and knee arthroplasty
🇩🇰Copenhagen, Denmark